Status:
COMPLETED
Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas
Lead Sponsor:
University of California, San Francisco
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Brain and Central Nervous System Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
RATIONALE: Diagnostic procedures, such as magnetic resonance imaging (MRI) and magnetic resonance spectroscopic imaging (MRSI), (done before, during, and after treatment) may help doctors predict a pa...
Detailed Description
OBJECTIVES: * Determine the magnetic resonance spectroscopic imaging (MRSI) characteristics of patients who are undergoing treatment for supratentorial glioma. * Determine the survival of patients wh...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Histologically confirmed supratentorial glioma
- Grade II-IV disease
- Previously untreated disease
- Eligible for surgical resection and/or chemotherapy with or without radiotherapy
- Tumor accessible by magnetic resonance spectroscopic imaging
- PATIENT CHARACTERISTICS:
- Karnofsky performance status 60-100%
- Life expectancy ≥ 8 weeks
- Not pregnant
- No contraindication for magnetic resonance examinations, including any of the following:
- Cardiac pacemaker or fibrillator
- Aneurysm clip
- Insulin or infusion pump
- Any implant held in place by a magnet
- Metal contamination anywhere in the body
- PRIOR CONCURRENT THERAPY:
- No prior chemotherapy
- No prior radiotherapy
- No prior treatment for the malignancy
Exclusion
Key Trial Info
Start Date :
November 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT00274755
Start Date
November 1 2003
Last Update
May 20 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States, 94115